Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- Check3 days agoChange DetectedThe NIH announcement banner about its terminology transition and related updates is no longer displayed.SummaryDifference1%

- Check10 days agoChange DetectedThe footer revision label updates from v3.7.2 to v3.8.0. The page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check17 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check24 days agoChange DetectedThe site footer revision label changed from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check52 days agoChange DetectedAccess to the NCT03290079 study record is now blocked by a 403 Forbidden page, replacing the previous study content and navigation. The change means users cannot view the trial details on ClinicalTrials.gov until access is restored.SummaryDifference18%

Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.